Please assess the completion status of the following clinical trial:

Trial Title: Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (For Infant Group):~* Healthy full-term infant after birth, Apgar score ≥7.~* Guardian signed informed consent.~* Guardian can comply with the requirements of the clinical trial.~* Without administering immunoglobulin during the following period.~* Axillary temperature ≤37.0 ℃.~Inclusion Criteria (For Other Age Groups):~* More than 1 month old healthy people, without the history of hepatitis B infection.~* Subjects or their guardians signed informed consent.~* After questioning medical history, physical examination and being judged as healthy subject.~* Without the history of hepatitis B vaccination.~* Subjects or their guardians can comply with requirements of the clinical trail.~* Without other prevention drugs or immunoglobulin administered within two weeks before the clinical trail or during the following period.~* Axillary temperature ≤37.0 ℃.~Exclusion Criteria (For Infant Group):~* Apgar score of infant after birth \<7.~* With nervous system damage after birth, or with the family history of mental illness, epilepsy or encephalopathy.~* With immune system dysfunction.~* With vitamin deficiency.~* With acute febrile diseases, or infectious diseases.~* With congenital malformations, developmental disorders or serious chronic illness.~* With thrombocytopenia or other coagulation disorders.~* Administered immunoglobulin during the period of the clinical trail, especially administered Hepatitis B immunoglobulin to the infant of Hepatitis B infected mother.~* With endemic disease.~* Participate another clinical trial during the period of the clinical trail.~* Any circumstance that may affect clinical trail evaluation.~Exclusion Criteria (For Other Age Groups):~* With allergies, seizures, epilepsy, encephalopathy or with family history of mental illness.~* Allergic to any component of the study vaccine.~* With immune system dysfunction.~* Hepatitis B infected people.~* Anti-HBs was positive screened by ELISA kit.~* Either anti-HBs ≥10mIU/ml or HBsAg was positive screened by Radioimmunoassay method.~* With acute febrile diseases or infectious diseases.~* With congenital malformations, developmental disorders or serious chronic illness.~* With thrombocytopenia or other coagulation disorders.~* With the history of severe allergic reactions.~* Administered other prevention drugs or immunoglobulin within two weeks before the clinical trail or during the following period.~* With any acute illness that requires antibiotics or anti-viral treatment within 7 days before the clinical trail.~* With vitamin deficiency.~* With the history of febrile convulsion.~* Axillary temperature ≥38.0 ℃ within 3 days before the clinical trail.~* Participate another clinical trial during the period of the clinical trail.~* Pregnant woman.~* Any circumstance that may affect clinical trail evaluation.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 10µg/0.5ml hepatitis B vaccine (Type: EXPERIMENTAL): 3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
- 5µg/0.5ml hepatitis B vaccine (Type: ACTIVE_COMPARATOR): 3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete